Multivariate analyses for OS (treatment adjusted)
| Multivariate models . | Prognostic factors . | HR . | 95% CI . | P . | P* . |
|---|---|---|---|---|---|
| Model A | Fludarabine-refractoriness | 4.1 | 1.75-9.64 | .001 | .005 |
| BIRC3 mutation | 3.41 | 1.15-10.12 | .027 | .835 | |
| Cluster #3 & #4 | 2.91 | 1.52-5.60 | .001 | .003 | |
| Model B | Fludarabine-refractoriness | 3.53 | 1.51-8.22 | .003 | .014 |
| BIRC3 mutation | 4.79 | 1.57-14.61 | .006 | .786 | |
| Multiple-hit profile | 2.85 | 1.37-5.94 | .005 | .025 |
| Multivariate models . | Prognostic factors . | HR . | 95% CI . | P . | P* . |
|---|---|---|---|---|---|
| Model A | Fludarabine-refractoriness | 4.1 | 1.75-9.64 | .001 | .005 |
| BIRC3 mutation | 3.41 | 1.15-10.12 | .027 | .835 | |
| Cluster #3 & #4 | 2.91 | 1.52-5.60 | .001 | .003 | |
| Model B | Fludarabine-refractoriness | 3.53 | 1.51-8.22 | .003 | .014 |
| BIRC3 mutation | 4.79 | 1.57-14.61 | .006 | .786 | |
| Multiple-hit profile | 2.85 | 1.37-5.94 | .005 | .025 |
Both models include variables with P < .1 in univariate analysis (Binet/RAI staging, fludarabine-refractoriness, BIRC3 mutation, trial). In addition, model 1 includes clusters 3 and 4 vs 1 and 2, and model 2 includes cluster 3 (multiple-hit profile) vs 1, 2, and 4.
After bootstrapping process (1000 samples).